Incyte (INCY) Expected to Post Quarterly Earnings on Thursday

Key Points

• Incyte is expected to report Q3 2026 results before markets open on October 29. Analysts project a loss of $3.64 per share and revenue of approximately $1.47 billion; its earnings call is scheduled for 8:00 a.m. ET.
• The company’s previous quarter exceeded expectations, with EPS of $3.09 versus the $2.15 consensus and revenue of $1.67 billion, up 37.7% year over year.
• Analyst sentiment is mixed, with 12 Buy, 12 Hold and one Sell rating, producing an overall “Hold” consensus and an average price target of $129.90. Insiders have sold 55,342 shares worth about $6.66 million over the past 90 days.

Incyte (NASDAQ:INCY - Get Free Report) is projected to release its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Incyte to post earnings of ($3.64) per share and revenue of $1.47 billion for the quarter. Investors may visit the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Incyte (NASDAQ:INCY - Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.15 by $0.94. The firm had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.50 billion. Incyte had a net margin of 27.71% and a return on equity of 29.93%. The company's revenue for the quarter was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.57 EPS. On average, analysts expect Incyte to post $2.28 EPS for the current fiscal year and $7.61 EPS for the next fiscal year.

Incyte Price Performance

NASDAQ:INCY opened at $113.44 on Thursday. The firm has a market capitalization of $22.99 billion, a price-to-earnings ratio of 14.69, a price-to-earnings-growth ratio of 4.17 and a beta of 0.74. Incyte has a one year low of $84.02 and a one year high of $132.60. The business has a fifty day moving average price of $121.56 and a 200-day moving average price of $111.33.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on INCY. HC Wainwright reiterated a "buy" rating and set a $152.00 target price on shares of Incyte in a research report on Tuesday, October 13th. Morgan Stanley began coverage on Incyte in a research report on Tuesday. They issued an "equal weight" rating and a $119.00 price target for the company. Wall Street Zen cut Incyte from a "buy" rating to a "hold" rating in a research report on Saturday, October 10th. Citigroup reaffirmed a "buy" rating on shares of Incyte in a research note on Monday, August 3rd. Finally, UBS Group reaffirmed a "neutral" rating and issued a $127.00 price objective on shares of Incyte in a research note on Monday, October 5th. Twelve equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $129.90.

Insider Activity at Incyte

In other Incyte news, EVP Patrick Mayes sold 41,899 shares of the company's stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $119.46, for a total value of $5,005,254.54. Following the completion of the transaction, the executive vice president directly owned 61,441 shares in the company, valued at $7,339,741.86. This represents a 40.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pablo Cagnoni sold 10,801 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the sale, the insider directly owned 183,200 shares of the company's stock, valued at approximately $23,002,592. This trade represents a 5.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 55,342 shares of company stock valued at $6,659,208 over the last 90 days. 16.20% of the stock is currently owned by corporate insiders.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.